Chemistry:EDP-305

From HandWiki
Short description: Chemical compound
EDP-305
EDP-305.svg
Legal status
Legal status
  • Investigational
Identifiers
PubChem CID
Chemical and physical data
FormulaC36H58N2O5S
Molar mass630.93 g·mol−1
3D model (JSmol)

EDP-305 is a non-bile acid farnesoid X receptor (FXR) agonist developed by Enanta Pharmaceuticals for non-alcoholic fatty liver disease.[1][2] According to preclinical research CYP3A4 is the main enzyme used to metabolize the drug and there is a low potential for drug interactions.[3]

References

  1. Ratziu, Vlad; Rinella, Mary E.; Neuschwander-Tetri, Brent A.; Lawitz, Eric; Denham, Douglas; Kayali, Zeid; Sheikh, Aasim; Kowdley, Kris V. et al. (March 2022). "EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study". Journal of Hepatology 76 (3): 506–517. doi:10.1016/j.jhep.2021.10.018. PMID 34740705. 
  2. An, Ping; Wei, Guangyan; Huang, Pinzhu; Li, Wenda; Qi, Xiaolong; Lin, Yi; Vaid, Kahini A.; Wang, Jun et al. (July 2020). "A novel non-bile acid FXR agonist EDP-305 potently suppresses liver injury and fibrosis without worsening of ductular reaction". Liver International 40 (7): 1655–1669. doi:10.1111/liv.14490. PMID 32329946. 
  3. Ahmad, Alaa; Adda, Nathalie (September 2022). "Assessment of drug–drug interaction potential with EDP -305, a farnesoid X receptor agonist, in healthy subjects". Clinical and Translational Science 15 (9): 2146–2158. doi:10.1111/cts.13348. PMID 35675500.